Generex Biotechnology Corporation Granted Additional Time to Comply With NASDAQ Listing Requirement

WORCESTER, Mass., July 25, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has been notified by The Nasdaq Stock Market that the bid price of its common stock had closed below $1.00 for 30 consecutive business days. In accordance with NASDAQ Marketplace Rule 4450(e)(2), the Company was granted 180 calendar days, or until January 20, 2009, to regain compliance with the Minimum Bid Price Rule. If the bid price for the Company's common stock closes at $1.00 per share for more than 10 consecutive business days within the period provided, the Company will have achieved compliance. The Company intends to monitor the bid price for its common stock and consider options available to the Company to achieve compliance with NASDAQ listing standards.
MORE ON THIS TOPIC